Cathepsin D in Breast Cancer

Overview

Journal Breast Cancer Res Treat

Specialty Oncology

Date 1990 Jul 1

PMID 2207345

Citations 24

Authors

H ROCHEFORT

Affiliations

Soon will be listed here.

Abstract

Cathepsin D is an acidic lysosomal protease present in all cells. In estrogen receptor positive and negative breast cancer cell lines, the mRNA coding for pro-cathepsin D is overexpressed and sorting and maturation of the pro-enzyme are altered, leading to accumulation of the active proteinase in large endosomes and to secretion of the precursor (52K protein). In MCF7 cells, the cathepsin D mRNA is induced directly and transcriptionally by estrogens and indirectly by growth factors. In vitro, pro-cathepsin D is an autocrine mitogen on breast cancer cells and can be auto-activated to degrade extracellular matrix and proteoglycans and to activate other proteinases in acidic microenvironments. In patients, there is a significant correlation between high cathepsin D concentrations in the cytosol of primary breast cancer and development of metastasis. This marker is independent of other prognostic factors and appears to be particularly useful in lymph node-negative tumors. These results suggest that overexpression and possible derouting of cathepsin D plays an important role in invasion and metastasis of breast cancer.

Citing Articles

A New Cathepsin D Targeting Drug Delivery System Based on Immunoliposomes Functionalized with Lipidated Pepstatin A.

Kozak A, Mikhaylov G, Khodakivskyi P, Goun E, Turk B, Vasiljeva O Pharmaceutics. 2023; 15(10).

PMID: 37896224 PMC: 10609775. DOI: 10.3390/pharmaceutics15102464.

Proteins Found in the Triple-Negative Breast Cancer Secretome and Their Therapeutic Potential.

McHenry P, Prosperi J Int J Mol Sci. 2023; 24(3).

PMID: 36768435 PMC: 9916912. DOI: 10.3390/ijms24032100.

Breast ductal lavage for assessment of breast cancer biomarkers.

Chatterton Jr R, Parker N, Habe-Evans M, Bryk M, Scholtens D, Khan S Horm Cancer. 2011; 1(4):197-204.

PMID: 21533003 PMC: 3082955. DOI: 10.1007/s12672-010-0021-y.

Immunoaffinity enrichment and liquid chromatography-selected reaction monitoring mass spectrometry for quantitation of carbonic anhydrase 12 in cultured renal carcinoma cells.

Rafalko A, Iliopoulos O, Fusaro V, Hancock W, Hincapie M Anal Chem. 2010; 82(21):8998-9005.

PMID: 20936840 PMC: 3046293. DOI: 10.1021/ac101981t.

Genes, chromatin, and breast cancer: an epigenetic tale.

Mielnicki L, Asch H, Asch B J Mammary Gland Biol Neoplasia. 2001; 6(2):169-82.

PMID: 11501577 DOI: 10.1023/a:1011356623442.

References

Spyratos F, Maudelonde T, Brouillet J, Brunet M, Defrenne A, Andrieu C . Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet. 1989; 2(8672):1115-8. DOI: 10.1016/s0140-6736(89)91487-6. View

Maudelonde T, Domergue J, Henquel C, Freiss G, Brouillet J, Simony J . Tamoxifen treatment increases the concentration of 52K-cathepsin D and its precursor in breast cancer tissue. Cancer. 1989; 63(7):1265-70. DOI: 10.1002/1097-0142(19890401)63:7<1265::aid-cncr2820630706>3.0.co;2-z. View

Maudelonde T, Khalaf S, Garcia M, Freiss G, Duporte J, Benatia M . Immunoenzymatic assay of Mr 52,000 cathepsin D in 182 breast cancer cytosols: low correlation with other prognostic parameters. Cancer Res. 1988; 48(2):462-6. View

Rio M, Bellocq J, Daniel J, Tomasetto C, Lathe R, Chenard M . Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa. Science. 1988; 241(4866):705-8. DOI: 10.1126/science.3041593. View

Maudelonde T, Martinez P, Brouillet J, Laffargue F, Pages A, ROCHEFORT H . Cathepsin-D in human endometrium: induction by progesterone and potential value as a tumor marker. J Clin Endocrinol Metab. 1990; 70(1):115-21. DOI: 10.1210/jcem-70-1-115. View

Brouillet J, Theillet C, Maudelonde T, Defrenne A, Simony-Lafontaine J, Sertour J . Cathepsin D assay in primary breast cancer and lymph nodes: relationship with c-myc, c-erb-B-2 and int-2 oncogene amplification and node invasiveness. Eur J Cancer. 1990; 26(4):437-41. DOI: 10.1016/0277-5379(90)90012-i. View

Capony F, Rougeot C, Montcourrier P, Cavailles V, Salazar G, ROCHEFORT H . Increased secretion, altered processing, and glycosylation of pro-cathepsin D in human mammary cancer cells. Cancer Res. 1989; 49(14):3904-9. View

Pagano M, Capony F, ROCHEFORT H . [Pro-cathepsin D can activate in vitro pro-cathepsin B secreted by ovarian cancers]. C R Acad Sci III. 1989; 309(1):7-12. View

Faust P, Kornfeld S, Chirgwin J . Cloning and sequence analysis of cDNA for human cathepsin D. Proc Natl Acad Sci U S A. 1985; 82(15):4910-4. PMC: 390467. DOI: 10.1073/pnas.82.15.4910. View

10.

Cavailles V, Garcia M, Salazar G, Domergue J, Simony J, Pujol H . Immunodetection of estrogen receptor and 52,000-dalton protein in fine needle aspirates of breast cancer tumors. J Natl Cancer Inst. 1987; 79(2):245-52. View

11.

Cavailles V, Augereau P, Garcia M, ROCHEFORT H . Estrogens and growth factors induce the mRNA of the 52K-pro-cathepsin-D secreted by breast cancer cells. Nucleic Acids Res. 1988; 16(5):1903-19. PMC: 338189. DOI: 10.1093/nar/16.5.1903. View

12.

ROCHEFORT H, Cavailles V, Augereau P, Capony F, Maudelonde T, Touitou I . Overexpression and hormonal regulation of pro-cathepsin D in mammary and endometrial cancer. J Steroid Biochem. 1989; 34(1-6):177-82. DOI: 10.1016/0022-4731(89)90080-0. View

13.

Morisset M, Capony F, ROCHEFORT H . The 52-kDa estrogen-induced protein secreted by MCF7 cells is a lysosomal acidic protease. Biochem Biophys Res Commun. 1986; 138(1):102-9. DOI: 10.1016/0006-291x(86)90252-4. View

14.

Capony F, Garcia M, Capdevielle J, Rougeot C, Ferrara P, ROCHEFORT H . Purification and first characterization of the secreted and cellular 52-kDa proteins regulated by estrogens in human-breast cancer cells. Eur J Biochem. 1986; 161(2):505-12. DOI: 10.1111/j.1432-1033.1986.tb10471.x. View

15.

Lippman M, Dickson R, Bates S, Knabbe C, Huff K, Swain S . 8th San Antonio Breast Cancer Symposium--Plenary lecture. Autocrine and paracrine growth regulation of human breast cancer. Breast Cancer Res Treat. 1986; 7(2):59-70. DOI: 10.1007/BF01806790. View

16.

Freiss G, Vignon F, Pau B, Paolucci F, ROCHEFORT H . A two-site immunoenzymometric assay of 52-kDa pro-cathepsin D, and its use in human breast diseases. Clin Chem. 1989; 35(2):234-7. View

17.

Touitou I, Cavailles V, Garcia M, Defrenne A, ROCHEFORT H . Differential regulation of cathepsin D by sex steroids in mammary cancer and uterine cells. Mol Cell Endocrinol. 1989; 66(2):231-8. DOI: 10.1016/0303-7207(89)90035-x. View

18.

Garcia M, Pages A, Richer G, Domergue J, Pages A, Cavalie G . Distribution of the Mr 52,000 estrogen-regulated protein in benign breast diseases and other tissues by immunohistochemistry. Cancer Res. 1986; 46(7):3734-8. View

19.

Briozzo P, Morisset M, Capony F, Rougeot C, ROCHEFORT H . In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by breast cancer cells. Cancer Res. 1988; 48(13):3688-92. View

20.

Capony F, Morisset M, Barrett A, Capony J, Broquet P, Vignon F . Phosphorylation, glycosylation, and proteolytic activity of the 52-kD estrogen-induced protein secreted by MCF7 cells. J Cell Biol. 1987; 104(2):253-62. PMC: 2114416. DOI: 10.1083/jcb.104.2.253. View